C12N 2310/312
Phosphonates
C12N2310/312 (Phosphonates) appears on 353 US grants and 519 published applications in this corpus.
Search patents in C12N- Granted patents
- 353
- Published applications
- 519
- Assignees
- 161
- Inventors
- 809
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 2 | 0 |
| 1993 | 4 | 0 |
| 1994 | 2 | 0 |
| 1995 | 4 | 0 |
| 1996 | 12 | 0 |
| 1997 | 22 | 0 |
| 1998 | 15 | 0 |
| 1999 | 15 | 0 |
| 2000 | 11 | 0 |
| 2001 | 13 | 2 |
| 2002 | 12 | 7 |
| 2003 | 8 | 22 |
| 2004 | 8 | 21 |
| 2005 | 4 | 8 |
| 2006 | 7 | 7 |
| 2007 | 4 | 8 |
| 2008 | 4 | 8 |
| 2009 | 6 | 10 |
| 2010 | 10 | 6 |
| 2011 | 10 | 4 |
| 2012 | 8 | 12 |
| 2013 | 4 | 9 |
| 2014 | 6 | 11 |
| 2015 | 13 | 30 |
| 2016 | 12 | 11 |
| 2017 | 12 | 17 |
| 2018 | 8 | 10 |
| 2019 | 8 | 19 |
| 2020 | 10 | 21 |
| 2021 | 16 | 25 |
| 2022 | 8 | 39 |
| 2023 | 16 | 53 |
| 2024 | 17 | 58 |
| 2025 | 26 | 49 |
| 2026 | 16 | 52 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof6 Oct 2026US 12,753,409 B2Hangzhou Tianlong Pharmaceutical Co., Ltd.
- Modified oligonucleotides targeting SNPs28 Jul 2026US 12,692,498 B2University of Massachusetts
- Compositions and methods for modulating SCAP activity7 Jul 2026US 12,674,169 B2Dicerna Pharmaceuticals, Inc.
- RNAi agents for inhibiting expression of Beta-ENaC, compositions thereof, and methods of use16 Jun 2026US 12,655,428 B2Arrowhead Pharmaceuticals, Inc.
- Oligonucleotides for SOD1 modulation16 Jun 2026US 12,655,432 B2University of Massachusetts
- Sugar Modified Oligonucleotides and Uses Thereof8 Oct 2026US 2026/0308587 A1Ionis Pharmaceuticals, Inc.
- Treatment of gpam related diseases and disorders8 Oct 2026US 2026/0308594 A1Empirico Inc.
- Nucleic Acid Antisense Oligomer Readthrough of Nonsense Codons1 Oct 2026US 2026/0297572 A1University of Massachusetts
- Short interfering nucleic acid (sina) molecules targeting angptl 3 and angptl 8 and methods of using the same1 Oct 2026US 2026/0297581 A1Aligos Therapeutics, Inc.
- Pcsk9 irna compositions and methods of use thereof1 Oct 2026US 2026/0297586 A1Alnylam Pharmaceuticals, Inc.
Most cited
By later US patents
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997
- Oligonucleotides having phosphorothioate linkages of high chiral purity626US 5,587,361 AIsis Pharmaceuticals, Inc. · 1996
- Oligonucleotides containing N-2 substituted purines621US 5,587,469 AIsis Pharmaceuticals, Inc. · 1996
- Substituted purines and oligonucleotide cross-linking603US 5,681,941 AIsis Pharmaceuticals, Inc. · 1997